Is sofosbuvir and velpatasvir (Epclusa) a new drug for the treatment of hepatitis C?

Sofosbuvir and velpatasvir (Epclusa) combination is another hepatitis C direct antiviral drug from the American company Gilead based onsofosbuvir. It is composed of sofosbuvir(Sofosbuvir) 400mg+Velpatasvir(Velpatasvir) 100mg composite tablet (SOF/VEL). It is the world's only fully oral, pan-genotypic, single-tablet new drug for the treatment of hepatitis C. It is suitable for treating all six genotypes of hepatitis C. Patient types include non-cirrhosis or compensated cirrhosis (Child-Pugh Class A), and decompensated cirrhosis (Child-Pugh Class B or C). It is more effective than the previous two generations of products, has fewer side effects, shorter treatment time, and can be cured in just 12 weeks.